Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KinLET: Lutetium Lu 177 Edotreotide in Pediatric SSTR-positive Tumors
NCT06441331Phase 1Recruiting
- Sponsor
- ITM Isotope Technologies Munich
- Start
- Sep 2025
- Primary completion
- Jun 2028
- Modality
- Peptide-Drug Conjugates
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of lutetium Lu 177-edotreotide in neuroendocrine tumor (NET), Neuroendocrine Neoplasm (NEN), lymphoma and 5 more, sponsored by ITM Isotope Technologies Munich. Primary endpoint: Pediatric Dosage at 8 weeks. Started Sep 2025; status: recruiting.
02
Drugs
lutetium Lu 177-edotreotide
03
Conditions
neuroendocrine tumor (NET)Neuroendocrine Neoplasm (NEN)lymphomasolid tumorcentral nervous system tumor
Beyond the preview
Go deeper on NCT06441331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441331.